Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08).

As of September 30, 2021, Regulus had $35.8 million in cash and cash equivalents.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.